Respiratory syncytial virus: A prioritized or neglected target?

Future Medicinal Chemistry

Volumn 2, Issue 10, 2010, Pages 1523-1527

  Roymans, Dirk ^a   Koul, Anil ^a  

^a Johnson and Johnson ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALN RSV 01; ANTIVIRUS AGENT; MOTAVIZUMAB; PALIVIZUMAB; RSV 604; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; FOOD AND DRUG ADMINISTRATION; HAEMOPHILUS INFLUENZAE; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPROMISED PATIENT; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; NONHUMAN; NOTE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK BENEFIT ANALYSIS; RNA INTERFERENCE; STREPTOCOCCUS PNEUMONIA; VACCINATION; VIRAL BRONCHIOLITIS;

ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; INFANT, NEWBORN; MODELS, MOLECULAR; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SMALL MOLECULE LIBRARIES; VIRAL PROTEINS; YOUNG ADULT;

EID: 77958109715     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.235     Document Type: Note

References (41)

1. Nair H, Nokes JD, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545-1555 (2010
2. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull. World Health Organ. 86(5), 408-416 (2008
3. Simoes EAF. Respiratory syncytial virus infection. Lancet 354(9181), 847-852 (1999
4. Sigurs N, Gustafsson PM, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Cri. Care Med. 171(2), 137-141 (2005
5. Simoes EA, Groothuis JR, Carbonell-Estrany X et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151(1), 34-42 (2007
6. Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus in young children. N. Engl. J. Med. 360(6), 588-598 (2009
7. Madhi SA, Levine OS, Hajjeh R, Mansoor OD, Cherian T. Vaccines to prevent pneumonia and improve child survival. Bull. World Health Organ. 86(5), 365-372 (2008
8. Murata Y, Falsey AR. Respiratory syncytial virus infection in adults. Antivir. Ther. 12(4), 659-670 (2007
9. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352(17), 1749-1759 (2005
10. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J. Am. Med. Assoc. 289(2), 179-186 (2003 (Pubitemid 36068705)
11. Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect. Dis. 5(9), 106 (2009
12. Carbonell-Estrany X, Simões EA, Dagan R et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125(1), e35-51 (2010
13. Young D. FDA: MedImmune's Rezield has 3x allergic reactions as Synagis. BioWorld Today 21(104), 1-5 (2010
14. Murata Y. Respiratory syncytial virus vaccine development. Clin. Lab. Med. 29(4), 725-739 (2009
15. Haas MJ. Besieging RSV. SciBX 2(1), 1-3 (2009
16. Nokes JD, Cane PA. New strategies for control of respiratory syncytial virus infection. Curr. Opin. Infect. Dis. 21(6), 639-643 (2008
17. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89(4), 405-421 (1969
18. Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422-434 (1969
19. Neilson KA, Yunis EJ. Demonstration of respiratory syncytial virus in an autopsy series. Pediatr. Pathol. 10(4), 491-502 (1990
20. Delgado MF, Coviello S, Monsalvo AC et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15(1), 34-41 (2009
21. Bueno SM, González PA, Pacheco R et al. Host immunity during RSV pathogenesis. Int. Immunopharmacol. 8(10), 1320-1329 (2008
22. Welliver TP, Garofalo RP, Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 195(8), 1126-1136 (2007
23. Devincenzo J, Lambkin-Williams R, Wilkinson T et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl Acad. Sci. USA 107(19), 8800-8805 (2010
24. Bonfanti JF, Roymans D. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr. Opin. Drug Dev. 12(4), 479-487 (2009
25. Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial virus infection. Expert Opin. Emerg. Drugs 14(2), 207-217 (2009
26. Chapman J, Abbott E, Alber DG et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51(9), 3346-3353 (2007
27. Lamb RA, Jardetzky TS. Structural basis of viral invasion: lessons from paramyxovirus F. Curr. Opin. Struct. Biol. 17(4), 427-436 (2007
28. Roymans D, De Bondt HL, Arnoult E et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Natl Acad. Sci. USA 107(1), 308-313 (2010
29. Cianci C, Langley DR, Dischino DD et al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Natl Acad. Sci. USA 101(42), 15046-15051 (2004
30. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 168(6), 633-639 (2003
31. Aung S, Rutigliano JA, Graham BS. Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. J. Virol. 75(20), 9918-9924 (2001
32. Welliver RC. The immune response to respiratory syncytial virus infection: friend or foe? Clinic. Rev. Allerg. Immunol. 34(2), 163-173 (2008
33. DeVincenzo JP. A new direction in understanding the pathogenesis of respiratory syncytial virus bronchiolitis: how real infants suffer. J. Infect. Dis. 195(8), 1084-1086 (2007
34. Buckingham SC, Jafri HS, Bush AJ et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J. Infect. Dis. 185(9), 1222-1228 (2002
35. Ermers MJJ, Rovers MM, van Woensel JB et al. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomized double blind placebo controlled trial. BMJ 338, b897 (2009
36. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J. Infect. Dis. 191(11), 1861-1868 (2005
37. Buckingham SC, Bush A, DeVincenzo JP. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr. Infect. Dis. J. 19(2), 113-117 (2000
38. Hall CB. Respiratory syncytial virus in young children. Lancet 375(9725), 1500-1502 (2010
39. Keeping the promise: a forward-looking review to promote an agreed action agenda to achieve the Millennium Development Goals by 2015. United Nations, New York, NY, USA (2010). www.un.org/millenniumgoals
40. Global action plan for prevention and control of pneumonia (GAPP). WHO-Unicef, Geneva, Switzerland (2009). http://whqlibdoc.who.int/hq/2009/WHO- FCH-CAH-NCH-09.04-eng.pdf
41. Clinical Trials. http://clinicaltrials.gov